Bayer stock holds below recent high as investors weigh glyphosate hearing risk

Bayer (ISIN DE000BAY0017) stock is trading in the upper half of its 52-week range in late August 2026, with the shares closing at €47.90 on August 21, 2026 on Xetra, 0.9 percent lower on the day. A recent overview of the share performance highlights that this level leaves the company some distance below its latest 52-week high, while a key glyphosate court hearing is scheduled for September 14, 2026. For investors, the combination of a still-intact medium-term uptrend and looming legal risks is shaping the risk-reward debate.

Medium-term uptrend remains intact

According to a recent market commentary the August 21, 2026 close of €47.90 on Xetra places Bayer shares about 2.4 percent above their 50-day moving average, underscoring that the medium-term trend is still pointed upward. The same analysis notes that the stock trades well above its 200-day moving average, reinforcing the picture of a longer-term recovery phase after previous weakness.

The 52-week high for the stock currently stands at €53.86, so Bayer would need to gain roughly €5.96 from the August 21, 2026 closing level to retest that peak. That gap corresponds to an upside of slightly more than 12 percent from €47.90, highlighting that the shares are closer to the middle of their one-year range than to the top. For equity investors, this quantified distance to the recent high is an important reference point when deciding whether current levels already discount upcoming risks.

Legal overhang from glyphosate hearing

The same August 23, 2026 report points out a scheduled glyphosate-related hearing on September 14, 2026, which could influence sentiment toward Bayer stock. Litigation connected with glyphosate-based products has been a recurring theme for the company, and each new court date can potentially change investor perceptions of future settlement costs and legal liabilities.

From a portfolio perspective, the explicit date of September 14, 2026 gives a clear time horizon over which event risk is elevated. Some investors may choose to scale positions ahead of the hearing, while others may see any share price volatility around that date as an entry opportunity if the fundamental earnings profile remains intact.

Latest share price and market context

Real-time quote data compiled on August 22, 2026 shows Bayer shares changing hands at €48.04 on Xetra, matching the last recorded closing price for that trading day. A detailed quote overview lists the Bayer share at €48.04 as of August 22, 2026, confirming only a modest move from the €47.90 close on August 21, 2026. This limited day-to-day change suggests that the market has not dramatically repriced the stock in advance of the September hearing.

In addition, intraday order-book snapshots from Xetra show bid-ask levels clustered just under €48.00 during the late afternoon session on August 21, 2026, with individual trades reported at €47.82, €47.84, and related prices. In that same session, a trading summary reported an Xetra quote of €47.90 at 16:27 on August 21, 2026, down €0.71 or 1.46 percent versus the previous close. The combination of a small pullback and a still-elevated position against moving averages reinforces the picture of consolidation inside an ongoing uptrend.

Bayer pharmaceuticals pipeline and focus product

Bayer is active across pharmaceuticals, consumer health, and crop science, with a portfolio that ranges from cardiovascular therapies to oncology and radiology products. A prominent example from its prescription medicine lineup is the oral anticoagulant Xarelto, which has been a key driver of cardiovascular franchise revenue in recent years. As patent protections evolve and competition intensifies, the way Bayer manages lifecycle extensions and new indications for such flagship therapies remains crucial for the long-term earnings trajectory.

Bayer stock and current valuation context

Based on the latest available Xetra data, Bayer stock closed at €47.90 on August 21, 2026, while a separate real-time snapshot recorded the shares at €48.04 on August 22, 2026. These prices place the company well below its 52-week high of €53.86, yet above key moving averages, suggesting that investors assign some value to the companys pipeline and restructuring efforts but still demand a discount for legal and execution risks. How the September 14, 2026 glyphosate hearing unfolds could determine whether the shares move closer to their recent peak or re-test lower support levels.

Company facts

Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra
Price (as of August 22, 2026): €48.04
Sector / Industry: Pharmaceuticals / Life sciences